US 12,257,306 B2
Antiviral prodrugs and nanoformulations thereof
Howard E. Gendelman, Omaha, NE (US); and Benson Edagwa, Omaha, NE (US)
Assigned to Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed by Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed on Oct. 27, 2022, as Appl. No. 18/050,351.
Application 18/050,351 is a continuation of application No. 17/309,435, previously published as PCT/US2019/063498, filed on Nov. 27, 2019.
Claims priority of provisional application 62/772,852, filed on Nov. 29, 2018.
Prior Publication US 2024/0100171 A1, Mar. 28, 2024
Int. Cl. A61K 47/55 (2017.01); A61K 9/14 (2006.01); A61P 31/18 (2006.01)
CPC A61K 47/55 (2017.08) [A61K 9/146 (2013.01); A61P 31/18 (2018.01)] 8 Claims
OG exemplary drawing
 
1. A compound, or a pharmaceutically acceptable salt or stereoisomer thereof, comprising:
(a) a first bictegravir molecule;
(b) a second bictegravir molecule; and
(c) a linker, wherein the linker covalently attaches the first and second bictegravir molecules.